Breaking News

CPhI Forecasts Record EBITDAs for CDMOs in 2022

Booster vaccines & capacity constraints during a period of high R&D investment are driving up prices for specialized facilities, advanced therapies & biologics.

Author Image

By: Charlie Sternberg

Associate Editor

Part one of the 2021 CPhI Annual Report predicts an increasingly bullish outlook for CDMOs in the next 2-3 years, with macro factors significantly driving up demand and prices for mergers and acquisitions.   The full findings (featuring 10+ experts and insights from 350 companies) will be launched in Milan at the CPhI Worldwide (9-11 November, 2021 at Fiera Milano and 25 October – 19 November online), the world’s largest pharma event. However, an advanced copy will be sent to anyone who re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters